Tivantinib
- Generic Name
- Tivantinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H19N3O2
- CAS Number
- 905854-02-6
- Unique Ingredient Identifier
- PJ4H73IL17
- Background
Tivantinib has been investigated in Solid Tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 29
- Registration Number
- NCT02150733
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin
- Conditions
- Interventions
- First Posted Date
- 2014-01-29
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Armando Santoro, MD
- Target Recruit Count
- 31
- Registration Number
- NCT02049060
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Rozzano, Milan, Italy
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT01861301
- Locations
- 🇺🇸
Illinois CancerCare-Peoria, Peoria, Illinois, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸City of Hope South Pasadena, South Pasadena, California, United States
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
- First Posted Date
- 2012-12-24
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 383
- Registration Number
- NCT01755767
Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2012-12-13
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT01749384
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2015-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT01725191
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
Effect of Tivantinib on the QTC Interval in Cancer Subjects
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 38
- Registration Number
- NCT01699061
- Locations
- 🇺🇸
START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 81
- Registration Number
- NCT01696955
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸City of Hope South Pasadena, South Pasadena, California, United States
Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery
- First Posted Date
- 2012-09-20
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT01688973
- Locations
- 🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸Columbus NCI Community Oncology Research Program, Columbus, Ohio, United States
🇺🇸The Mark H Zangmeister Center, Columbus, Ohio, United States
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT01654965
- Locations
- 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.